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Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare 
primary immunodeficiency disorder typically caused by biallelic autoimmune regulator 
(AIRE) mutations that manifests with chronic mucocutaneous candidiasis (CMC) and 
autoimmunity. Patients with STAT1 gain-of-function (GOF) mutations also develop CMC 
and autoimmunity; they exhibit increased STAT1 protein levels at baseline and STAT1 
phosphorylation (pSTAT1) upon interferon (IFN)-γ stimulation relative to healthy controls. 
AIRE interacts functionally with a protein that directly regulates STAT1, namely protein 
inhibitor of activated STAT1, which inhibits STAT1 activation. Given the common clinical 
features between patients with AIRE and STAT1 GOF mutations, we sought to determine 
whether APECED patients also exhibit increased levels of STAT1 protein and phosphor-
ylation in CD14+ monocytes. We obtained peripheral blood mononuclear cells from 8 
APECED patients and 13 healthy controls and assessed the levels of STAT1 protein and 
STAT1 tyrosine phosphorylation at rest and following IFN-γ stimulation, as well as the 
levels of STAT1 mRNA. The mean STAT1 protein levels in CD14+ monocytes exhibited 
a ~20% significant decrease in APECED patients both at rest and after IFN-γ stimula-
tion relative to that of healthy donors. Similarly, the mean peak value of IFN-γ-induced 
pSTAT1 level was ~20% significantly lower in APECED patients compared to that in 
healthy controls. The decrease in STAT1 and peak pSTAT1 in APECED patients was 
not accompanied by decreased STAT1 mRNA or anti-IFN-γ autoantibodies; instead, 
it correlated with the presence of autoantibodies to type I IFN and decreased AIRE−/− 
monocyte surface expression of IFN-γ receptor 2. Our data show that, in contrast to 
patients with STAT1 GOF mutations, APECED patients show a moderate but consistent 
and significant decrease in total STAT1 protein levels, associated with lower peak levels 
of pSTAT1 molecules after IFN-γ stimulation.
Keywords: sTaT1, phosphorylation, chronic mucocutaneous candidiasis, AIRE, aPeceD, cD14+ monocytes, 
iFn-γ
Abbreviations: APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; APS-1, autoimmune polyglan-
dular syndrome type-1; CC, coiled-coil; CMC, chronic mucocutaneous candidiasis; DB, DNA binding; GOF, gain-of-function; 
LOF, loss-of-function; PBMC, peripheral blood mononuclear cells; STAT, signal transducer and activator of transcription.
Table 1 | Clinical manifestations of the eight autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy patients included in this study.
Manifestationa number of 
affected patients
% of affected 
patients
Adrenal insufficiency 7 88
Asplenia 1 13
Autoimmune hepatitis 2 25
Alopecia 1 13
B12 deficiency 3 38
Chronic mucocutaneous candidiasis 7 88
Enamel hypoplasia 8 100
Gastritis 3 38
Gonadal failure 3 38
Early-onset hypertension 4 50
Hypoparathyroidism 8 100
Hypothyroidism 3 38
Intestinal dysfunction 6 75
Keratoconjunctivitis 1 13
Nail dystrophy 1 13
Tubulointerstitial nephritis 1 13
Pneumonitis 2 25
Sjogren’s-like syndrome 3 38
Urticarial eruption 3 38
Vitiligo 1 13
aThe manifestations are presented in alphabetical order.
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inTrODUcTiOn
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystr-
ophy (APECED) or autoimmune polyglandular syndrome type-1 
(APS-1; OMIM 240300) is a monogenic disorder caused by 
biallelic mutations in the autoimmune regulator (AIRE) gene, a 
thymus-enriched transcription regulator that promotes central 
immune tolerance via the expression of peripheral tissue self-
antigens in medullary thymic epithelial cells (1, 2). Additional 
AIRE functions have recently been proposed to also contribute 
to immunological tolerance (3–6). In addition, heterozygous 
dominant-negative AIRE mutations in the plant homeodomain 1 
domain have also been described, associated with organ-specific 
APECED-associated autoimmune manifestations and/or chronic 
mucocutaneous candidiasis (CMC) (7–9). APECED patients 
manifest with a characteristic constellation of CMC and autoim-
munity that involves both endocrine and non-endocrine tissues 
(10–12). In fact, APECED is the only CMC-associated primary 
immunodeficiency disorder in which CMC is the sole consistent 
infectious disease phenotype. In addition to the breakdown in 
mechanisms of T-cell tolerance, AIRE-deficient patients also have 
high titers of neutralizing autoantibodies against Th17 cytokines 
and tissue-specific autoantigens, which have been shown to 
correlate with the development of CMC and organ-specific 
autoimmune manifestations, respectively (13–15). In addition, 
APECED patients exhibit a decreased frequency of peripheral 
blood IL-17-producing CD4+ T cells following PMA/ionomycin 
stimulation [(3, 15), Lionakis, unpublished observations].
Heterozygous STAT1 gain-of-function (GOF) mutations 
were initially implicated in causing autosomal-dominant CMC 
(16, 17) but have thereafter also been associated with the 
development of autoimmunity that can involve endocrine and 
non-endocrine tissues (16–19); beyond these common clinical 
features between APECED and STAT1 GOF mutations, patients 
with STAT1 GOF mutations also develop a broad-spectrum of 
infectious, inflammatory, and vascular manifestations not seen 
in APECED (19). These STAT1 mutations are considered GOF 
because of enhanced phosphorylated STAT1 molecules upon 
interferon (IFN)-γ stimulation (17, 20). Impaired production of 
Th17 cytokines by T-cells has been implicated in the pathogenesis 
of CMC in these patients (17, 19, 20).
Due to the overlap in CMC and other clinical features 
between patients with APECED and STAT1 GOF mutations, 
and because AIRE interacts functionally with a protein inhibitor 
of activated STAT1 (PIAS1), which inhibits STAT1 activation 
(21, 22), we aimed to study STAT1 protein level and phospho-
rylation upon IFN-γ stimulation in patients with AIRE mutations 
and determine whether human AIRE deficiency phenocopies the 
cell-intrinsic enhanced STAT1 levels seen in patients with STAT1 
GOF mutations.
MaTerials anD MeThODs
study Participants
Eight APECED patients were enrolled (2015–2017) on a NIAID 
IRB-approved protocol and provided written informed consent. 
All eight had a clinical diagnosis of APECED based on the 
development of any two manifestations within the classic triad 
of CMC, hypoparathyroidism, and adrenal insufficiency. The 
most common clinical manifestations among the eight APECED 
patients included CMC (88%), hypoparathyroidism (100%), 
adrenal insufficiency (88%), and enamel hypoplasia (100%). The 
full list and frequencies of clinical manifestations of the eight 
APECED patients are outlined in Table 1. The most common 
AIRE mutant allele in these eight patients was c.967_979del13 
(60%), followed by c.769C>T (13%). Two patients were com-
pound heterozygous for c.967_979del13 and c.769C>T, while 
the remaining six patients had six different AIRE genotypes. 
Samples from a patient carrying the c.1057G>A E353K STAT1 
GOF mutation and a patient with the autosomal dominant form 
of IFN-γ receptor 1 deficiency carrying the 818del4 mutation 
were also collected under a NIAID IRB-approved protocol 
and provided written informed consent. Healthy volunteer 
blood samples from 13 individuals were obtained for STAT1 
protein evaluation and from 10 individuals for STAT1 mRNA 
level determination under IRB-approved protocols through 
the Department of Transfusion Medicine, at the NIH Clinical 
Center. The study was conducted in accordance with the Helsinki 
Declaration.
Peripheral blood Mononuclear cells 
(PbMc) isolation and intracellular staining 
for sTaT1 and psTaT1
STAT1 protein and pSTAT1 levels were examined using flow 
cytometry in paired APECED patients and healthy control 
individuals in seven independent experiments at rest and up 
to 60  min after IFN-γ stimulation. Each patient and healthy 
donor was evaluated only once. In six of the seven independent 
experiments, a single APECED patient was evaluated along with 
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two accompanying healthy donors, and in one experiment two 
APECED patients were evaluated together with one accompany-
ing healthy donor.
PBMC were isolated by density-gradient centrifugation using 
lymphocyte separation media (Lonza) and resuspended in RPMI 
culture media (Gibco), supplemented with pyruvate (100  mM, 
Sigma Aldrich), glutamate (200 mM, Life Technologies), penicil-
lin/streptomycin (100 U/100 μg/ml, Life Technologies), 10% fetal 
bovine serum (Serum Source International) and HEPES (20 mM, 
General Electric).
Intracellular phosphorylated STAT1 (pSTAT1) and total 
STAT1 were determined by FACS analysis, as previously 
described (18, 23). Freshly isolated PBMC were resuspended at 
106 cells per 100 µl in RPMI and were serum starved for 30 min, 
in polystyrene round-bottom tubes (Becton Dickinson Falcon). 
Cells were then incubated with FITC-conjugated anti-human 
CD14 (Becton Dickinson cat# 555397). Cells were then stimu-
lated with IFN-γ (800 U/ml) for 15, 30, or 60 min at 37°C, fixed 
with 2% Paraformaldehyde (Electron Microscopy Sciences) at 
37°C for 10 min, permeabilized with 100% methanol in dark on 
ice for 30 min, washed with PBS/2%FBS, and incubated for 1 h in 
the dark at 4°C with combinations of PerCP–Cy5.5-conjugated 
anti-human pSTAT1 (Y701) (Becton Dickinson cat# 560113) 
and Alexa Fluor 647-conjugated anti-human N-terminus STAT1 
(Becton Dickinson cat# 558560) with Fix and Perm Medium B 
(Life technologies). Alexa Fluor 647-conjugated IgG1 isotype con-
trol (Becton Dickinson cat# 557783) was used. Baseline pSTAT1 
levels were used as a control for the specificity of the PerCP–Cy5.5-
conjugated anti-human pSTAT1 antibody, by comparing between 
pSTAT1 levels as expressed in geometric mean of fluorescence-at 
rest and after stimulation. Samples were washed once with 
PBS/2%FBS and resuspended in 1% Paraformaldehyde. All data 
were collected with LSR Fortessa or LSRII (Becton Dickinson) 
and analyzed with FlowJo software (Treestar, Ashland, OR, USA).
iFn-α, iFn-ω, and iFn-γ autoantibody 
Detection
A particle-based multiplex assay was used to detect IFN-α, 
IFN-ω, and IFN-γ autoantibodies in the serum or plasma samples 
from the eight APECED patients and compared with healthy 
control subjects (n = 100) enrolled through the NIH Blood Bank, 
as previously described (24).
iFn-γ receptors 1 and 2 expression on 
Monocytes
Frozen PBMC from eight APECED patients and eight healthy 
donors were used for measuring IFN-γ receptors 1 and 2 levels on 
CD14+ monocytes. Cells were resuspended at 106 cells per 100 µl 
in PBS and incubated with LIVE/DEAD® Fixable Aqua Dead Cell 
Stain Kit (ThermoFisher) in 4°C followed by staining with FITC-
conjugated anti-human CD14 (Becton Dickinson cat# 555397), 
PE-conjugated anti CD119 (IFN-γ receptor 1; IFN-γR1; Becton 
Dickinson cat# 558937), or APC-conjugated anti-IFN-γ recep-
tor 2 (IFN-γR2; R&D cat# FAB773A) for 30 min. PE-conjugated 
IgG2b κ isotype control (Cat# 555058) and APC-conjugated 
IgG isotype control (R&D cat# IC108A) were used for control 
staining. Cells were then washed with PBS/2%FBS and fixed with 
1% PFA. Data were collected with LSRII (Becton Dickinson) and 
analyzed with FlowJo software (Treestar, Ashland, OR, USA). 
The geometric mean fluorescence intensity on monocytes for 
each receptor was calculated after subtracting the geometric 
mean fluorescence intensity of the corresponding isotype control 
staining.
sTaT1 mrna expression Determination
Frozen PBMC from the 8 APECED patients and 10 healthy donors 
were used for measuring STAT1 mRNA expression by quantitative 
PCR (qPCR). To determine the percent of live CD14+ monocytes 
within PBMC, an aliquot of the PBMC was incubated with LIVE/
DEAD® Fixable Violet Dead Cell Stain Kit (ThermoFisher) in 4°C 
followed by staining with FITC-conjugated anti-human CD14 
(Becton Dickinson cat# 555397). Data were collected with LSRII 
(Becton Dickinson) and analyzed with FlowJo software (Treestar, 
Ashland, OR, USA). Among the live PBMC, the mean percentage 
of CD14+ monocytes was similar in the patient and healthy donor 
groups: 7.2 ± 0.8 vs. 7.7 ± 1.7, respectively (p = 0.75). For mRNA 
extraction, the RNeasy kit (Qiagen) was used, according to the 
manufacturer’s instructions. To convert mRNA to cDNA, the high-
capacity cDNA reverse transcription kit (Applied Biosystems) was 
used. qPCR was then performed with TaqMan detection (TaqMan® 
Universal Master Mix II, with UNG; ThermoFisher), using the 
7,500 real-time PCR system (Applied Biosystems) and predesigned 
primer and probe mixes for glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH; ThermoFisher) or STAT1 (ThermoFisher). 
All qPCR assays were performed in duplicate and results were 
normalized to GAPDH transcript levels using the threshold cycle 
(Ct) method.
aire sequencing
Genomic DNA was extracted from whole blood, amplified and 
sequenced for AIRE exons and flanking splice sites as previously 
described (25).
statistical analysis
The geometric mean of fluorescence for pSTAT1 or STAT1 
protein levels was calculated using the FlowJo software and the 
values obtained from APECED patients were normalized to the 
values obtained from the same-day healthy control samples. All 
results were expressed as mean ±  SEM unless otherwise indi-
cated. Statistical analyses were performed by Student’s t-test or 
Mann–Whitney U test, where appropriate, using the GraphPad 
Prism 7 software (La Jolla, CA, USA). A p value of less than 0.05 
was considered significant.
resUlTs
We enrolled eight APECED patients from eight non- 
consanguineous families with clinical and genetic diagnosis of 
APECED. Two (25%) were male and six (75%) were female. The 
mean patient age was 22 years (range, 9–56 years); 3 (38%) were 
children, with a mean age of 11 years. Thirteen healthy donors 
were enrolled for same-day harvesting and comparative analyses 
FigUre 1 | Autoimmune regulator deficiency results in a decrease in STAT1 protein levels in human monocytes. (a) Representative depiction of pSTAT1 level at rest 
and up to 30 min after interferon (IFN)-γ stimulation in CD14+ cells of a STAT1 gain-of-function (GOF) patient (orange), an autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) patient (red), a patient with the autosomal dominant form of IFN-γR1 deficiency (black) and a healthy donor (blue)  
(b) Representative depiction of STAT1 protein level at rest and up to 30 min after IFN-γ stimulation in CD14+ cells of a STAT1 GOF patient (orange), an APECED 
patient (red), and a healthy donor (blue). Protein and phosphorylation levels are expressed in geometric mean of fluorescence (Geo. Mean), as measured by flow 
cytometry. STAT1 total protein (c) and pSTAT1 (D) levels in CD14+ cells of APECED patients (n = 8; red dots) and healthy donors (n = 13; blue dots) at rest (time 0) 
and up to 60 min after IFN-γ stimulation. Total protein and phosphorylation levels are expressed in % of the same-day control average values, for each time 
point—0, 15, 30, and 60 min, separately. (e) Area under the curve of CD14+ cells STAT1 phosphorylation vs. time in APECED patients (n = 8; red dots) and healthy 
donors (n = 13; blue dots). (F) STAT1 mRNA level, relative to glyceraldehyde-3-phosphate dehydrogenase, in peripheral blood mononuclear cells of healthy donors 
(n = 10) and APECED patients (n = 8) at rest. ns, not significant. *p < 0.05; **p < 0.01, by t-test. Quantitative data represent mean ± SEM.
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of STAT1 and pSTAT1 protein levels. A STAT1 GOF patient 
was tested as control for enhanced STAT1 protein and pSTAT1 
levels [patient 1 in Ref. (20)], and a patient with the autosomal 
dominant form of IFN-γR1 deficiency [patient described in the 
case report in Ref. (26)] was tested as control for absent IFN-γ-
induced pSTAT1 stimulation (Figures 1A,B).
We examined STAT1 protein and pSTAT1 levels in paired 
APECED patients and healthy control individuals, at rest and up 
to 60 min after IFN-γ stimulation. We focused on IFN-γ because 
it induces STAT1 phosphorylation and homo-dimerization with-
out the involvement of other STAT molecules as in the case of 
STAT1–STAT2 heterodimer formation induced by IFN-α stimu-
lation (27, 28). We also focused on CD14+ monocytes because 
of their relatively high levels of IFN-γ receptors 1 and 2, which 
allows for detection of rapid activation of STAT1 (29).
In all the eight tested APECED patients, STAT1 protein 
levels were lower than the same-day healthy donors mean levels 
(Figure 1C). The eight patients’ mean CD14+ monocyte STAT1 
protein level at rest was ~80% of that observed in healthy donors 
(p = 0.003). After IFN-γ stimulation, the significant decrease in 
CD14+ monocyte mean STAT1 protein level of APECED patients 
persisted at all examined time-points throughout the 60 min of 
the experiment (Figure 1C).
Consistent with previous reports (23), we found that pSTAT1 
induction peaked 15  min after IFN-γ stimulation and started 
to decline toward baseline at 30 min after stimulation in all 13 
healthy donor monocytes (Figure 1A). Similar kinetics of pSTAT1 
induction peak and decline were observed in all eight APECED 
patients (Figure 1A). APECED patient monocytes’ mean pSTAT1 
levels at rest were not significantly different compared to healthy 
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donor levels at rest (108.7 ± 9.2% vs. 100 ± 2.83%, respectively, 
p = 0.29; Figure 1D). However, the mean peak pSTAT1 level of 
the APECED patients was 20% decreased compared to that seen 
in healthy donors at 15 min (80 ± 4.5% vs. 100 ± 4.5%, respec-
tively. p = 0.008). Thereafter, at 30 min after IFN-γ stimulation, 
the patients’ mean pSTAT1 level was lower than healthy donors 
(87 ± 5.1% vs. 100 ± 3.9%, respectively), and the difference was 
close to statistical significance (p = 0.06), whereas at 60 min after 
IFN-γ stimulation the differences in pSTAT1 levels between 
the patients and healthy donors groups were not significant 
(91 ± 5.5% vs. 100 ± 4.3%, respectively, p = 0.25; Figure 1D). 
We also calculated the area under the curve (AUC) of STAT1 
phosphorylation (expressed as geometric mean of fluorescence) 
vs. time (expressed as minutes) for up to 60  min after IFN-γ 
stimulation in both groups and compared patient AUC level to the 
same-day healthy donor average. Consistent with the mean peak 
pSTAT1 values, APECED patients mean AUC levels were ~15% 
decreased relative to those seen in healthy controls (p = 0.025, 
Figure  1E). Because Th17  cells are decreased in peripheral 
blood of APECED [(3, 15), Lionakis, unpublished observations] 
and STAT1 GOF patients (17, 19, 20), our findings collectively 
indicate that the Th17 frequency decrease in AIRE deficiency is 
not caused by a STAT1 GOF state in peripheral blood monocytes.
Because among the eight APECED patients, seven different 
AIRE genotypes were observed, reflecting the greater genetic 
diversity of APECED in North America (25), we were not able 
to examine whether there is a correlation between specific AIRE 
mutations and the degree of pSTAT1 and total STAT1 levels in 
AIRE-deficient monocytes.
Given the decreased STAT1 protein levels seen in APECED 
patients, we asked whether STAT1 is also decreased at the mRNA 
level in APECED patients. Thus, we compared STAT1 mRNA 
levels by qPCR in PBMC of 8 APECED patients and 10 healthy 
donors and found them to be similar (p = 0.32) (Figure 1F).
Because APECED patients are known to have autoantibodies 
against cytokines, we examined whether autoantibodies to type 
I IFNs or IFN-γ were present in the serum of the eight APECED 
patients, which could potentially affect the levels of pSTAT1 in the 
patients group, after IFN-γ stimulation. All eight tested patients 
had autoantibodies to IFN-α and IFN-ω, while no patient had 
autoantibodies to IFN-γ (Figure 2A).
Given the decreased peak pSTAT1 level after IFN-γ stimula-
tion in AIRE-deficient monocytes, we also asked whether the 
surface expression of IFN-γ receptors 1 and 2 is decreased in the 
monocytes of the eight APECED patients using flow cytometry. 
We found no difference in the expression of IFN-γR1 between 
healthy donor and APECED monocytes but a significant ~40% 
decrease in surface expression of IFN-γR2 in patient monocytes 
(mean fluorescence intensity 186.4 ±  14.61 vs. 117.3 ±  10.68, 
p = 0.002, respectively, Figure 2B).
DiscUssiOn
Because of the similarities in clinical presentation of CMC and 
autoimmunity and decreased peripheral blood Th17 frequencies 
between patients with APECED and STAT1 GOF mutations, 
our study examined STAT1 protein and phosphorylation levels 
in patients with APECED and shows that APECED patient 
monocytes do not share the same cell-intrinsic increase in STAT1 
protein and phosphorylation levels as cells from patients with 
STAT1 GOF mutations. In fact, our findings reveal a moderate 
but consistent and significant decrease in STAT1 protein and 
phosphorylation levels in APECED CD14+ monocytes at rest and 
after IFN-γ stimulation.
Until recently, it had been postulated that impaired nuclear 
dephosphorylation is the underlying cause of increase in pSTAT1 
levels in patients with STAT1 GOF mutations (17, 19, 20). 
Nonetheless, recent reports have described normal dephospho-
rylation rates in some patients with a STAT1 GOF mutations; 
for example, Sobh et  al. (30), Meesilpavikkai et  al. (31), and 
Weinacht et al. (32) described three new STAT1 GOF mutations 
in the SH2 (p.H629Y and p.V653I) and linker (p.E545K) domains 
with enhanced pSTAT1 levels but normal dephosphorylation. 
In addition, Tabellini and colleagues recently reported high levels 
of STAT1 protein in NK cells from seven patients carrying five dif-
ferent CC or DNA binding (DB) domain STAT1 GOF mutations 
(23). Similarly, high STAT1 protein levels were found in CD14+ 
monocytes and CD3+ T cells of 12 patients with 10 different CC, 
DB, or SH2 domain STAT1 GOF mutations (Zimmerman and 
Holland, submitted manuscript). After controlling the STAT1 GOF 
patients’ pSTAT1 levels for the corresponding total STAT1 protein 
levels, STAT1 phosphorylation levels were normal (Zimmerman 
and Holland, submitted manuscript). These findings collectively 
support the hypothesis that high resting and IFN-γ-stimulated 
total STAT1 protein levels may serve as a background against 
which high pSTAT1 levels occur in some patients with STAT1 
GOF mutations. Alternatively, the pSTAT1 levels may not directly 
correlate with total STAT1 levels, as indicated in other reports 
(33). Future studies using more STAT1 GOF and STAT1 loss-of-
function (LOF) patients will be needed to determine the temporal 
dynamics and correlation of total and pSTAT1 molecules.
In our study, based on the presence of CMC and other shared 
clinical features between APECED and STAT1 GOF mutation 
patients, we tested the hypothesis that AIRE deficiency enhances 
STAT1 cellular responses as a result of enhanced STAT1 protein 
and phosphorylation levels. Instead, we found a ~20% decrease in 
STAT1 protein and peak pSTAT1 levels in APECED patients; the 
decrease in total STAT1 levels could indicate that the decreased 
STAT1 protein level may be a determining factor for the decreased 
peak STAT1 phosphorylation levels observed in APECED CD14+ 
monocytes, although it could be accounted for by alternative fac-
tors that remain to be elucidated.
The molecular mechanism behind our finding is currently 
unknown. One possible explanation could have been that AIRE 
is involved in the regulation of STAT1 transcription; however, we 
found no significant difference in STAT1 mRNA levels between 
healthy donor and APECED PMBCs. Alternatively, AIRE may 
regulate STAT1 post-transcriptionally at the level of degrada-
tion or SUMOylation or other process directly or indirectly via 
known (e.g., PIAS1) or yet-unknown protein partners (21, 22). 
Alternatively, APECED patient autoantibodies against type I IFNs, 
which have been shown to exhibit the ability to neutralize and 
block IFN-α activity, STAT1 phosphorylation, and the expression 
of interferon-stimulated genes (34, 35), may adversely affect tonic 
FigUre 2 | The decrease in STAT1 protein and pSTAT1 levels seen in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients 
correlates with lower monocyte interferon (IFN)-γR2 receptor expression and the presence of type I IFN autoantibodies. (a) Sera from 8 APECED patients and 100 
healthy donors were evaluated for the presence of autoantibodies against IFN-γ, IFN-α, and IFN-ω. Shown is autoantibody immunoreactivity against the indicated 
cytokines expressed as fluorescence intensity using a particle-based multiplex assay. (b) IFN-γ receptor 1 and 2 levels were measured in CD14+ monocytes of 
healthy donors (n = 8) and APECED patients (n = 8). Summary data on mean fluorescence intensity and representative histogram FACS plots are shown. 
**p < 0.01; ****p < 0.0001, by Mann–Whitney U test (a) or t-test (b). Quantitative data represent median ± SEM.
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STAT1 expression in blood monocytes. The decrease in IFN-γR2 
expression on CD14+ monocytes may be a contributor to the 
decreased peak pSTAT1 levels in APECED patients’ cells. Future 
studies will be required to further examine this hypothesis as well 
as molecules and functional responses downstream of STAT1.
Impaired STAT1-dependent responses in patients with LOF 
STAT1 mutations or in patients with defects in the IFN-γ receptor 
signaling axis, underlie Mendelian susceptibility to mycobacterial 
disease (36). The defect in STAT1 levels post-IFN-γ stimulation 
that we observed in our APECED patients is modest relative 
to the complete absence of STAT1 phosphorylation following 
IFN-γ stimulation in patients with IFN-γ receptor deficiency 
[(23); Figure 1A]. Therefore, significant residual STAT1 signaling 
is functional in APECED patients to prevent the development of 
mycobacterial infections in these patients. Whether the decrease 
in STAT1 protein and phosphorylation that we identified is a 
contributing factor to the development of viral infections in some 
APECED patients [(37); Lionakis, unpublished observations] 
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remains to be elucidated. However, the decrease in STAT1 levels 
is unlikely to contribute to the pathogenesis of CMC as patients 
with defects in the IFN-γ receptor signaling axis do not have Th17 
defects and do not develop CMC (36). Hence, at this point, the 
biological and clinical implications of the decreased STAT1 levels 
in patients’ monocytes are unclear.
In summary, we describe an association between AIRE 
deficiency and a decrease in STAT1 protein level in primary 
human monocytes that is not accompanied by decreased STAT1 
mRNA levels but correlates with the presence of type I IFN 
autoantibodies and decreased monocyte surface expression of 
IFN-γR2. The mechanism behind this finding and its clinical 
and biological implications in APECED patients require further 
investigation.
eThics sTaTeMenT
Eight APECED patients were enrolled (2015–2017) on a NIAID 
IRB-approved protocol and provided written informed consent. 
Samples from a patient carrying the c.1057G>A E353K STAT1 
GOF mutation and a patient with the autosomal dominant form 
of IFN-γ receptor 1 deficiency carrying the 818del4 mutation were 
also collected under a NIAID IRB-approved protocol and provided 
written informed consent. Healthy volunteer blood samples from 
13 individuals were obtained for STAT1 protein evaluation and 
from 10 individuals for STAT1 mRNA level determination under 
IRB-approved protocols through the Department of Transfusion 
Medicine, at the NIH Clinical Center. The study was conducted in 
accordance with the Helsinki Declaration.
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